Mounjaro vs. Qsymia
Mounjaro and Qsymia differ significantly in mechanism and purpose. Mounjaro is a dual GIP and GLP-1 agonist for type 2 diabetes, with notable HbA1c reductions and moderate weight-loss benefits. Qsymia, a combination of phentermine and topiramate, is approved for chronic weight management, achieving more significant weight loss but without glucose benefits. Side effects also differ: Mounjaro commonly causes nausea, while Qsymia may lead to mood changes, insomnia, and stimulant-related risks. Mounjaro costs $1,135/month, substantially more than Qsymia’s $300/month. Neither drug currently faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Phentermine suppresses appetite by stimulating the release of norepinephrine in the brain; topiramate enhances feelings of fullness and alters taste perceptions, reducing food intake.
Common Side Effects
Dry mouth, insomnia, constipation, dizziness, and tingling in hands or feet.
Serious Potential Side Effects
Increased heart rate, mood changes, suicidal thoughts, and memory/concentration difficulties, dependency and abuse of medication